Explore our core discovery, potency evaluation, preclinical screening, and clinical services designed to furnish audit-ready eCTD Module 3 (CMC) and Module 4 (Nonclinical) filings.
In modern biopharmaceutical development, the transition from crude natural extracts to verifiable, reproducible New Drug Applications (NDAs) represents one of the most demanding regulatory pathways. Global authorities, including the United States Food and Drug Administration (US FDA) under its specialized Botanical Drug Development Guidance, the European Medicines Agency (EMA) Herbal Medicinal Products Committee (HMPC), and China's National Medical Products Administration (NMPA), have established stringent frameworks demanding that botanical drugs demonstrate chemical batch-to-batch consistency, defined mechanisms of action, and uncompromised safety profiles.
Regulatory Consensus: An ODM NDA Submission partner must bridge the chasm between traditional ethnopharmacology and modern molecular medicine. Botanical drugs are inherently multi-component therapeutics where the entire mixture is often defined as the active pharmaceutical ingredient (API). Demonstrating reproducibility requires non-destructive fingerprinting, multi-target pharmacodynamics, and end-to-end trace documentation across Good Agricultural and Collection Practices (GACP) through commercial cGMP synthesis.
The primary barrier to botanical NDA approval resides in eCTD Module 3. Traditional single-entity synthetic drugs isolate a 99%+ pure molecule. Botanical drug candidates contain dozens of homologous phyto-compounds, polyphenols, saponins, and polysaccharides. MedGence solves this through orthogonal chromatographic characterization.
Navigating Investigational New Drug (IND) clearance toward a final New Drug Application necessitates robust non-clinical pharmacological validation. Through cell-line disease phenotyping, target engagement assays, and GLP-compliant acute/chronic toxicological profiles, our scientific leadership ensures seamless translational milestones.
A regional dossier creates procurement friction. Global pharmaceutical brands require modular dossier structures that comply concurrently with US FDA 21 CFR 314, EMA Common Technical Document rules, and NMPA Category 1 innovative natural medicine mandates, drastically cutting multi-jurisdiction filing timelines.
Deploying a botanical active ingredient into clinical pipelines requires navigating conflicting regional pharmacopeias. Our regulatory affairs divisions in Changsha collaborate with global legal and toxicological advisory boards to calibrate chemistry, safety, and efficacy studies precisely to local health authority rubrics.
| Regulatory Framework | Target Jurisdiction | Primary Regulatory Hurdles | MedGence ODM Technical Assurance Solution |
|---|---|---|---|
| FDA 21 CFR 314 / 505(b)(2) | United States | Botanical raw material variability, unknown secondary active metabolites, multiple harvests. | Raw material fingerprinting across 3 harvest cycles; GAP documentation; batch release dissolution profiles; FDA pre-IND meeting support. |
| EMA THMPD / Well-Established Use | European Union | Stringent residual limit mandates (Ph. Eur. 2.8.13 pesticides, toxic pyrrolizidine alkaloids, aflatoxins). | Automated LC-MS/MS & GC-MS/MS pesticide screening (450+ analytes); supercritical extraction stripping; validated monograph compliance. |
| NMPA TCM Category 1 & 2 | China & APAC | Hospital preparation registration conversion, clinical efficacy endpoint verification, ancient formula modern rationale. | Modern medical elucidation of 83 classic TCM formulas; clinical evidence generation in top-tier University TCM hospitals; 56 historical hospital approvals. |
| ICH Common Technical Document (CTD) | Global Multi-Jurisdiction | Disparate stability zones (Zone IVb hot/humid), lack of validated stress testing and forced degradation kinetics. | Accelerated and real-time stability chambers (25°C/60% RH, 30°C/65% RH, 40°C/75% RH); photo-stability testing per ICH Q1B. |
Clinical data transferability often halts international NDA filings. We structure Phase I pharmacokinetic, dose-escalation, and Phase II/III randomized double-blind clinical trials within accredited tertiary research hospitals, utilizing ICH-E6 GCP guidelines to ensure multi-ethnic bridging data acceptability across western regulators.
MedGence develops and maintains active Type IV and Type II Drug Master Files submitted to regulatory bodies. This enables our ODM partners to reference critical manufacturing, processing, and analytical methodology under strict non-disclosure without disclosing proprietary engineering secrets to third-party resellers.
Should regulatory review boards issue Complete Response Letters (CRL) or information requests regarding phytochemical stability, impurity profiles, or elemental impurities (ICH Q3D), our multi-disciplinary analytical team formulates supplemental chromatographic protocols within compressed response timeframes.
Realized over 14+ years of dedicated natural medicine contract research, partnering with China's tier-one pharmaceutical conglomerates, military medical academies, and university hospitals.
Developing an active botanical ingredient for an NDA demands massive raw material inventory security. China commands over 70% of the world’s botanical harvesting, solvent extraction, and crystallization capacity. By integrating laboratory contract research (CRO) directly with industrial commercial manufacturing (CDMO) in Hunan, MedGence provides global clients an unparalleled economic and operational runway.
Botanical potency fluctuates wildly based on soil chemistry, latitude, altitude, and harvest timing. Our geographic origin evaluation databases encompass thousands of agricultural micro-climates across Yunnan, Guizhou, Sichuan, and Hunan provinces, ensuring year-round, standardized botanical biomass procurement that buffers against crop failure and geopolitically induced commodity shocks.
Transferring an analytical protocol from a 500 mL glass flask to a 10,000 L industrial extraction vessel often ruins botanical bioavailability due to thermal degradation or shearing forces. MedGence maintains in-house pilot plants and CDMO commercial facilities, ensuring critical process parameters (CPPs) established in the laboratory hold identical critical quality attributes (CQAs) at industrial tonnage.
Deploying an NDA through North American or Western European CDMOs often burdens emerging biotech firms with exorbitant capital expenditures and multi-year waiting lists. Utilizing China's specialized chemical and biological infrastructure delivers a 45% to 65% reduction in overall pre-formulation, analytical validation, and clinical manufacturing expenditure.
When Chief Scientific Officers, VPs of Regulatory Affairs, and Global Procurement Directors evaluate an overseas ODM NDA partner, technical competence must be reinforced with absolute risk insulation. We execute research under a rigid non-disclosure, work-for-hire entrustment legal architecture.
Clients retain 100% ownership of patented chemical compositions, extraction runbooks, purification fraction recipes, and formulation dossiers. No client data is combined or utilized for open-market retail formulas.
Every chromatographic test run, spectrophotometric reading, and clinical raw datum is recorded under 21 CFR Part 11 compliant digital architectures. Zero-deletion audit trails prevent data integrity disputes during regulatory site audits.
Certificates of Analysis (CoAs) are generated using multi-point chromatographic assays, screening for microbial bioburden, aflatoxins, polycyclic aromatic hydrocarbons (PAHs), heavy metals (ICP-MS), and residual extraction solvents.
Our milestone contractual structures tie delivery deadlines directly to regulatory submission windows. Whether furnishing stability batch release data or clinical supply packaging, timelines are operationally guaranteed.
The botanical drug industry is rapidly converging with computational biology. Historically perceived as an empirical, slow science, modern natural medicine discovery is powered by machine learning algorithms capable of mapping complex polypharmacological interactions.
Botanicals modulate multiple human receptors simultaneously. Utilizing deep neural network models, MedGence deconvolutes complex phytochemical cocktails to predict multi-target signaling cascades, cytokine reduction pathways, and synergistic anti-inflammatory or anti-metabolic disease mechanisms before initiating in vivo animal validations.
Moving beyond basic HPLC peaks, modern NDA dossiers require accurate mass assignments and fragment identification. Our state-of-the-art Quadrupole Time-of-Flight (Q-TOF) LC/MS systems map untargeted metabolomic profiles, pinpointing trace bioactive secondary metabolites that drive clinical efficacy.
Regulatory scrutiny over Class 1 and Class 2 volatile organic solvent residues (ICH Q3C) is intensifying. We engineer zero-toxic-residue processes utilizing deep eutectic solvents (DES), ultrasonic-assisted aqueous separation, and supercritical CO2 extraction with ethanol co-solvents, eliminating toxic environmental effluent.
From dietary supplement portfolio fortification to prescription-grade botanical drug market entry, MedGence supplies targeted contract manufacturing and regulatory frameworks tailored to specific corporate development pipelines.
Ideal for biotechs seeking expedited US approval. We reformulate proven natural entities with validated clinical safety history into modified-release or novel dosage formats, referencing prior clinical safety findings to dramatically slash Phase I trial expenditures.
For nutraceutical brands whose high-potency herbal extract possesses undeniable therapeutic efficacy. We elevate testing to cGMP pharma specifications, establish full CMC stability dossiers, and run formal Phase II studies to claim prescription market exclusivity.
Leveraging our successful track record of 56 hospital preparation registrations in China, we assist clinical institutions in transforming proprietary in-hospital master formulas into scalable, commercially stable pharmaceutical dosage forms ready for national licensing.
High-end cosmetic brands require botanical actives that can survive stringent regulatory review while providing clinical-grade efficacy data (anti-aging, melanogenesis suppression) verified by in vitro enzymatic and human skin-patch clinical trials.
Comprehensive answers addressing regulatory hurdles, supply chain logistics, IP preservation, and analytical validation protocols.
Procure individual preclinical testing studies or commission our full turnkey lab-to-commercial CDMO production infrastructure.
